Tenaya Therapeutics is trading at $0.40, up 8.27%, after its third-quarter results beat expectations. - In its November 4 report, the company posted a narrower loss of $0.08 per share, beating the cited consensus estimate, and $1.7 million in revenue versus roughly $0.8 million expected. - Tenaya reiterated its $66.8 million cash position and expected runway into Q4 2027; investors are watching for year-end clinical-data and regulatory updates.